Commercial agreement signed

An exciting day for Korecyte Bio! We have finalised a commercial contract with @KingsCollegeLon to pursue hypoxia-sensing #CART #Immunotherapy. A technology for treating solid cancers while avoiding off-tumour activation to lower toxicities for CAR-T.

The King’s article can be found here:

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies